Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT05395429Unknown

Clinical Evaluation of Genetron TERT/BRAF PCR Kit in Thyroid Cancer Patients

Role: lead

NCT05494853Unknown

Novel Biomarker Assay for Biomarker Assay for HCC Detection

Role: lead

NCT05400018Completed

Clinical Evaluation of Genetron D842V PCR Kit in GIST Patients

Role: lead

NCT05343832Unknown

Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients

Role: lead

NCT05100602Completed

Clinical Evaluation of Genetron TERT PCR Kit in Glioma Patients

Role: lead

NCT05100173Completed

Clinical Evaluation of Genetron IDH1 PCR Kit in Glioma Patients

Role: lead

NCT05023746Completed

Clinical Evaluation of Genetron Lung Cancer Panel in Non-small Cell Lung Cancer Patients

Role: lead

All 7 trials loaded